NASDAQ · LYEL
Lyell Immunopharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LYEL: Nov 11, 2026
Lyell Immunopharma, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.06. The reported EPS for the same quarter last year was $-2.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.06 | $-1.97 | $-2.14 | 4 |
| Dec 2026 | $-1.98 | $-1.77 | $-2.11 | 3 |
| Mar 2027 | $-2.27 | $-2.27 | $-2.27 | 1 |
| Jun 2027 | $-2.43 | $-2.43 | $-2.43 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · MarketBeat · RTTNews- Zacks · Oct 13, 8:35 AM EDTDown 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a TurnaroundLyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near
- BNK Invest · Oct 1, 4:35 PM EDTLyell Immunopharma Becomes Oversold (LYEL)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- Zacks · Jul 2, 9:55 AM EDTWall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Jun 4, 9:35 AM EDTLyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerLyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- MarketBeat · May 27, 4:03 AM EDTLyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline AdvancesLyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel. Seely described Lyell
- Zacks · May 19, 9:35 AM EDTDown 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- RTTNews · May 7, 11:47 AM EDTLyell Records $24 Mln Loss In Q1, Provides Updates On CAR-T Cell Therapies For Cancer Treatment(RTTNews) – Lyell Immunopharma Inc. (LYEL), a late-stage clinical company, released on Wednesday results from the first quarter, and provided updates on the developing pipeline of drug candidates.
- Fintel · Apr 10, 8:04 PM EDTNeedham Initiates Coverage of Lyell Immunopharma (LYEL) with Buy RecommendationFintel reports that on April 10, 2026, Needham initiated coverage of Lyell Immunopharma (NasdaqGS:LYEL) with a Buy recommendation. Analyst Price Forecast Suggests 79.19% Upside
- Fintel · Mar 9, 5:39 PM EDTCitizens Initiates Coverage of Lyell Immunopharma (LYEL) with Market Outperform RecommendationFintel reports that on March 9, 2026, Citizens initiated coverage of Lyell Immunopharma (NasdaqGS:LYEL) with a Market Outperform recommendation. Analyst Price Forecast Suggests 74.84% Upside
- Fintel · Jan 14, 6:54 PM ESTLyell Immunopharma (LYEL) Price Target Increased by 29.78% to 39.27The average one-year price target for Lyell Immunopharma (NasdaqGS:LYEL) has been revised to $39.27 / share. This is an increase of 29.78% from the prior estimate of $30.26 dated December 18, 2025. The price target is an average of many targets provided by ana
- Zacks · Dec 26, 2:33 AM ESTThe Zacks Analyst Blog Mineralys, Lyell, Insmed and NektarMineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
- Zacks · Dec 24, 10:51 AM EST4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to GrowMLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Lyell Immunopharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.